Comparison · NCT03643965-52e449cf
Nefecon vs Placebo Oral Capsule: Part B: Time to 30% Reduction in eGFR
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nefecon vs Placebo Oral Capsule: Part B: Time to 30% Reduction in eGFR. Trial comparisons, record NCT03643965-52e449cf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03643965-52e449cf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.115 | 0.0767 | 0.17 | wilson | |
| Risk in group 2 | 0.214 | 0.161 | 0.279 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0989 | -0.175 | -0.0226 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.538 | 0.33 | 0.878 | log | |
| Odds ratio, group 1 over group 2 | 0.478 | 0.269 | 0.851 | log | |
| Number needed to treat, for one fewer participant with the outcome on Nefecon than on Placebo Oral Capsule | 10.1 | 5.72 | 44.3 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nefecon | Nefecon 16 mg once daily by mouth for 9 months.~Nefecon: Nefecon 16 mg for daily administration by mouth for 9 months. | 21 | 182 | OG000 |
| Group 2 | Placebo Oral Capsule | Placebo oral capsule once daily by mouth for 9 months.~Placebo oral capsule: Placebo capsules for daily administration by mouth for 9 months. | 39 | 182 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Part B: Time to 30% Reduction in eGFR
- Description
Part B: Time to 30% reduction from baseline in eGFR (CKD-EPI) confirmed by a second value.~For clarity: Please note that the number of patients with a 30% reduction is presented with statistical analysis of the time to 30% reduction.
- Time frame
- Over 2 years
- Population
- Full analysis set - global study - Part B
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy
- NCT number
- NCT03643965
- Phases
- PHASE3
- Conditions
- Primary IgA Nephropathy
- Interventions
- Nefecon, Placebo oral capsule
- Lead sponsor
- Calliditas Therapeutics AB
- Results first posted
- 2024-12-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03643965?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03643965-52e449cf